Euro Biotechnology

[Source: Research & Innovation] The EBN TechCamp is the main EBN technical event where incubation and acceleration practitioners from EU|BICs all over Europe and beyond come together for mutual learning, experience exchange and enhancement of technical know-how.
The 8th EBN TechCamp is organised in partnership with ESA/ESTEC (Noordwijk, The Netherlands), on the 22-23 November 2018.
A fruitful and long-lasting cooperation with ESA/ESTEC is countinuing with a joint event of EU|BICs and ESA BICs where incubators and innovation practitioners will share and exchange best practices and incubation tools.

Nothing quite captured that 1990s internet aesthetic like GeoCities.
[Read More …]

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: REC-AG-2018Pillar: REC Programme 2014-2020Opening Date: Deadline: Tue, 9 Oct 2018 17:00:00 (Brussels local time)Modification Date: Mon, 1 Oct 2018Latest information: An updated version of the Questions and answers document has been added under Topic conditions and documents – Additional documents.

Asto CT, a startup developing a computed tomography (CT) device for performing diagnostic scans of animals, has raised nearly $1.1 million in new funding, according to a document filed with federal securities regulators.

Madison, WI-based Asto CT has now raised more than $1.7 million from investors, all of which has been debt financing, SEC filings show.

Asto CT’s device, known as Equina, is designed to allow horses and other animals to remain standing while it peers inside their legs, heads, and necks in search of illness or injury. That means veterinarians don’t have to put horses under general anesthesia, which… Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

White Biotechnology Market Report Provides Comprehensive Analysis Of: Key market segments and sub-segments, evolving market trends and …

[Source: Research & Innovation] Existing data suggest that immune reactions reduce the lifespan of animal-derived heart valves implanted in cardiac patients. An EU-funded project discovered how to overcome this limitation, to produce valves with improved biocompatibility and novel immunological strategies that will benefit younger patients in particular.

Adam Keeney has joined NodThera as president and CEO. He is also joining the company’s board of directors. Alan Watt, who had been serving as interim CEO, will resume his role as chief scientific officer of the Cambridge, UK, company. With Keeney’s appointment, NodThera will also open a new office in the Boston area. Keeney comes to NodThera from Sanofi (NYSE: SNY) subsidiary Genzyme, where he was global head of Sanofi Genzyme business development. Before Genzyme, Keeney held several roles at Johnson & Johnson (NYSE: JNJ). NodThera, which is developing treatments for diseases characterized by chronic inflammation, raised… Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

The window for life science IPOs is still open, and five biotechs and one medical device company chose the last week of the third quarter to make their stock market debuts. Gritstone Oncology (NASDAQ: GRTS) closed out the week by raising $100 million in an upsized  IPO.

On Thursday night, Emeryville, CA-based Gritstone priced its offering of 6.6 million shares at $15 apiece. The cancer drug company had planned to sell 6 million shares in the range of $13 to $15 each. According to its prospectus, Gritstone will use up to $25 million of the IPO cash to fund… Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

Eli Lilly has a blockbuster diabetes drug, dulaglutide (Trulicity), which helps the body make more insulin. But that drug, and others in the same class, are injectables. A number of companies are trying to offer patients a pill alternative.

Lilly (NYSE: LLY) now has a new pill drug candidate in its pipeline. The Indianapolis pharmaceutical giant has acquired rights to a Chugai diabetes drug that is ready to begin Phase 1 studies as a treatment for type 2 diabetes. According to deal terms announced late Thursday, Lilly will pay Tokyo-based Chugai $50 million up front in exchange for worldwide rights… Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

[Source: Research & Innovation] The International Cycling Safety Conference (ICSC) is a forum for researchers and experts in the field of cycling safety to exchange their knowledge and bring up new research topics or safety solutions.The Conferences are organised in a way to facilitate the interaction between the participants. All conference papers are publicly available at the conference web-sites. All papers submitted for the conference will be peer-reviewed by experts in the field. Selected scientific papers from the conference are often published in a special issue of a scientific journal.Topics for the conference include:- Cycling mobility- Bicycle accidentology, naturalistic observations and simulation studies- Cycling behaviour- Safety of children and young bicyclists- E-bikes- In-bicycle devices to improve safety- Road design, infrastructure, urban elements and traffic regulation- Bicycle-motor vehicle interactions: driver behaviour, active safety systems and automated vehicles